Global EGFR Inhibitors for Lung Cancer Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
The global market for EGFR Inhibitors for Lung Cancer is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key EGFR Inhibitors for Lung Cancer players cover Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global EGFR Inhibitors for Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global EGFR Inhibitors for Lung Cancer market, with both quantitative and qualitative data, to help readers understand how the EGFR Inhibitors for Lung Cancer market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the EGFR Inhibitors for Lung Cancer market and forecasts the market size by Type (Geftinib, Afatinib and Osimertinib), by Application (Medical Care, Experiment and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of EGFR Inhibitors for Lung Cancer, Research Methodology, etc.
Chapter 2: Executive Summary, global EGFR Inhibitors for Lung Cancer market size (sales and revenue) and CAGR, EGFR Inhibitors for Lung Cancer market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: EGFR Inhibitors for Lung Cancer sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global EGFR Inhibitors for Lung Cancer sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global EGFR Inhibitors for Lung Cancer market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma, Mylan, Boehringer Ingelheim, Teva Pharmaceuticals, Qilu Pharmaceutical and Betta Pharmaceuticals, etc.
Chapter 14: Research Findings and Conclusion
The global market for EGFR Inhibitors for Lung Cancer is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China EGFR Inhibitors for Lung Cancer market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key EGFR Inhibitors for Lung Cancer players cover Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma and Mylan, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global EGFR Inhibitors for Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global EGFR Inhibitors for Lung Cancer market, with both quantitative and qualitative data, to help readers understand how the EGFR Inhibitors for Lung Cancer market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the EGFR Inhibitors for Lung Cancer market and forecasts the market size by Type (Geftinib, Afatinib and Osimertinib), by Application (Medical Care, Experiment and Others,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Geftinib
- Afatinib
- Osimertinib
- Other
- Medical Care
- Experiment
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- AstraZeneca
- Genentech (Roche Group)
- Beta Pharma
- Mylan
- Boehringer Ingelheim
- Teva Pharmaceuticals
- Qilu Pharmaceutical
- Betta Pharmaceuticals
- Haosen Pharmaceutical
- ARIAD Pharmaceuticals
- HUTCHMED
- Shanghai Ellis
- Genvio Pharma
- Everest Pharmaceuticals
- Incepta Pharmaceuticals
- Jiangsu Hengrui Medicine
Chapter 1: Scope of EGFR Inhibitors for Lung Cancer, Research Methodology, etc.
Chapter 2: Executive Summary, global EGFR Inhibitors for Lung Cancer market size (sales and revenue) and CAGR, EGFR Inhibitors for Lung Cancer market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: EGFR Inhibitors for Lung Cancer sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global EGFR Inhibitors for Lung Cancer sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global EGFR Inhibitors for Lung Cancer market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Pfizer, AstraZeneca, Genentech (Roche Group), Beta Pharma, Mylan, Boehringer Ingelheim, Teva Pharmaceuticals, Qilu Pharmaceutical and Betta Pharmaceuticals, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Country/Region, 2017, 2022 & 2028
2.2 EGFR Inhibitors for Lung Cancer Segment by Type
2.2.1 Geftinib
2.2.2 Afatinib
2.2.3 Osimertinib
2.2.4 Other
2.3 EGFR Inhibitors for Lung Cancer Sales by Type
2.3.1 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
2.3.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Type (2017-2022)
2.3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022)
2.4 EGFR Inhibitors for Lung Cancer Segment by Application
2.4.1 Medical Care
2.4.2 Experiment
2.4.3 Others
2.5 EGFR Inhibitors for Lung Cancer Sales by Application
2.5.1 Global EGFR Inhibitors for Lung Cancer Sale Market Share by Application (2017-2022)
2.5.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Application (2017-2022)
2.5.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022)
3 GLOBAL EGFR INHIBITORS FOR LUNG CANCER BY COMPANY
3.1 Global EGFR Inhibitors for Lung Cancer Breakdown Data by Company
3.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Company (2020-2022)
3.1.2 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)
3.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Company (2020-2022)
3.2.1 Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022)
3.2.2 Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)
3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Company
3.4 Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers EGFR Inhibitors for Lung Cancer Product Location Distribution
3.4.2 Players EGFR Inhibitors for Lung Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR EGFR INHIBITORS FOR LUNG CANCER BY GEOGRAPHIC REGION
4.1 World Historic EGFR Inhibitors for Lung Cancer Market Size by Geographic Region (2017-2022)
4.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Geographic Region (2017-2022)
4.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Geographic Region
4.2 World Historic EGFR Inhibitors for Lung Cancer Market Size by Country/Region (2017-2022)
4.2.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Country/Region (2017-2022)
4.2.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Country/Region
4.3 Americas EGFR Inhibitors for Lung Cancer Sales Growth
4.4 APAC EGFR Inhibitors for Lung Cancer Sales Growth
4.5 Europe EGFR Inhibitors for Lung Cancer Sales Growth
4.6 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Growth
5 AMERICAS
5.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country
5.1.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
5.1.2 Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
5.2 Americas EGFR Inhibitors for Lung Cancer Sales by Type
5.3 Americas EGFR Inhibitors for Lung Cancer Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region
6.1.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022)
6.1.2 APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022)
6.2 APAC EGFR Inhibitors for Lung Cancer Sales by Type
6.3 APAC EGFR Inhibitors for Lung Cancer Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe EGFR Inhibitors for Lung Cancer by Country
7.1.1 Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
7.1.2 Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
7.2 Europe EGFR Inhibitors for Lung Cancer Sales by Type
7.3 Europe EGFR Inhibitors for Lung Cancer Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa EGFR Inhibitors for Lung Cancer by Country
8.1.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
8.1.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
8.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type
8.3 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer
10.3 Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer
10.4 Industry Chain Structure of EGFR Inhibitors for Lung Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 EGFR Inhibitors for Lung Cancer Distributors
11.3 EGFR Inhibitors for Lung Cancer Customer
12 WORLD FORECAST REVIEW FOR EGFR INHIBITORS FOR LUNG CANCER BY GEOGRAPHIC REGION
12.1 Global EGFR Inhibitors for Lung Cancer Market Size Forecast by Region
12.1.1 Global EGFR Inhibitors for Lung Cancer Forecast by Region (2023-2028)
12.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global EGFR Inhibitors for Lung Cancer Forecast by Type
12.7 Global EGFR Inhibitors for Lung Cancer Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer EGFR Inhibitors for Lung Cancer Product Offered
13.1.3 Pfizer EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered
13.2.3 AstraZeneca EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Genentech (Roche Group)
13.3.1 Genentech (Roche Group) Company Information
13.3.2 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered
13.3.3 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Genentech (Roche Group) Main Business Overview
13.3.5 Genentech (Roche Group) Latest Developments
13.4 Beta Pharma
13.4.1 Beta Pharma Company Information
13.4.2 Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered
13.4.3 Beta Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Beta Pharma Main Business Overview
13.4.5 Beta Pharma Latest Developments
13.5 Mylan
13.5.1 Mylan Company Information
13.5.2 Mylan EGFR Inhibitors for Lung Cancer Product Offered
13.5.3 Mylan EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Mylan Main Business Overview
13.5.5 Mylan Latest Developments
13.6 Boehringer Ingelheim
13.6.1 Boehringer Ingelheim Company Information
13.6.2 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered
13.6.3 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Boehringer Ingelheim Main Business Overview
13.6.5 Boehringer Ingelheim Latest Developments
13.7 Teva Pharmaceuticals
13.7.1 Teva Pharmaceuticals Company Information
13.7.2 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.7.3 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Teva Pharmaceuticals Main Business Overview
13.7.5 Teva Pharmaceuticals Latest Developments
13.8 Qilu Pharmaceutical
13.8.1 Qilu Pharmaceutical Company Information
13.8.2 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
13.8.3 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Qilu Pharmaceutical Main Business Overview
13.8.5 Qilu Pharmaceutical Latest Developments
13.9 Betta Pharmaceuticals
13.9.1 Betta Pharmaceuticals Company Information
13.9.2 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.9.3 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Betta Pharmaceuticals Main Business Overview
13.9.5 Betta Pharmaceuticals Latest Developments
13.10 Haosen Pharmaceutical
13.10.1 Haosen Pharmaceutical Company Information
13.10.2 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
13.10.3 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Haosen Pharmaceutical Main Business Overview
13.10.5 Haosen Pharmaceutical Latest Developments
13.11 ARIAD Pharmaceuticals
13.11.1 ARIAD Pharmaceuticals Company Information
13.11.2 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.11.3 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 ARIAD Pharmaceuticals Main Business Overview
13.11.5 ARIAD Pharmaceuticals Latest Developments
13.12 HUTCHMED
13.12.1 HUTCHMED Company Information
13.12.2 HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered
13.12.3 HUTCHMED EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 HUTCHMED Main Business Overview
13.12.5 HUTCHMED Latest Developments
13.13 Shanghai Ellis
13.13.1 Shanghai Ellis Company Information
13.13.2 Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered
13.13.3 Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Shanghai Ellis Main Business Overview
13.13.5 Shanghai Ellis Latest Developments
13.14 Genvio Pharma
13.14.1 Genvio Pharma Company Information
13.14.2 Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered
13.14.3 Genvio Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Genvio Pharma Main Business Overview
13.14.5 Genvio Pharma Latest Developments
13.15 Everest Pharmaceuticals
13.15.1 Everest Pharmaceuticals Company Information
13.15.2 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.15.3 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Everest Pharmaceuticals Main Business Overview
13.15.5 Everest Pharmaceuticals Latest Developments
13.16 Incepta Pharmaceuticals
13.16.1 Incepta Pharmaceuticals Company Information
13.16.2 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.16.3 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Incepta Pharmaceuticals Main Business Overview
13.16.5 Incepta Pharmaceuticals Latest Developments
13.17 Jiangsu Hengrui Medicine
13.17.1 Jiangsu Hengrui Medicine Company Information
13.17.2 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered
13.17.3 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Jiangsu Hengrui Medicine Main Business Overview
13.17.5 Jiangsu Hengrui Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for EGFR Inhibitors for Lung Cancer by Country/Region, 2017, 2022 & 2028
2.2 EGFR Inhibitors for Lung Cancer Segment by Type
2.2.1 Geftinib
2.2.2 Afatinib
2.2.3 Osimertinib
2.2.4 Other
2.3 EGFR Inhibitors for Lung Cancer Sales by Type
2.3.1 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
2.3.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Type (2017-2022)
2.3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022)
2.4 EGFR Inhibitors for Lung Cancer Segment by Application
2.4.1 Medical Care
2.4.2 Experiment
2.4.3 Others
2.5 EGFR Inhibitors for Lung Cancer Sales by Application
2.5.1 Global EGFR Inhibitors for Lung Cancer Sale Market Share by Application (2017-2022)
2.5.2 Global EGFR Inhibitors for Lung Cancer Revenue and Market Share by Application (2017-2022)
2.5.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022)
3 GLOBAL EGFR INHIBITORS FOR LUNG CANCER BY COMPANY
3.1 Global EGFR Inhibitors for Lung Cancer Breakdown Data by Company
3.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Company (2020-2022)
3.1.2 Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)
3.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Company (2020-2022)
3.2.1 Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022)
3.2.2 Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)
3.3 Global EGFR Inhibitors for Lung Cancer Sale Price by Company
3.4 Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers EGFR Inhibitors for Lung Cancer Product Location Distribution
3.4.2 Players EGFR Inhibitors for Lung Cancer Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR EGFR INHIBITORS FOR LUNG CANCER BY GEOGRAPHIC REGION
4.1 World Historic EGFR Inhibitors for Lung Cancer Market Size by Geographic Region (2017-2022)
4.1.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Geographic Region (2017-2022)
4.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Geographic Region
4.2 World Historic EGFR Inhibitors for Lung Cancer Market Size by Country/Region (2017-2022)
4.2.1 Global EGFR Inhibitors for Lung Cancer Annual Sales by Country/Region (2017-2022)
4.2.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue by Country/Region
4.3 Americas EGFR Inhibitors for Lung Cancer Sales Growth
4.4 APAC EGFR Inhibitors for Lung Cancer Sales Growth
4.5 Europe EGFR Inhibitors for Lung Cancer Sales Growth
4.6 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Growth
5 AMERICAS
5.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country
5.1.1 Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
5.1.2 Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
5.2 Americas EGFR Inhibitors for Lung Cancer Sales by Type
5.3 Americas EGFR Inhibitors for Lung Cancer Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region
6.1.1 APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022)
6.1.2 APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022)
6.2 APAC EGFR Inhibitors for Lung Cancer Sales by Type
6.3 APAC EGFR Inhibitors for Lung Cancer Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe EGFR Inhibitors for Lung Cancer by Country
7.1.1 Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
7.1.2 Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
7.2 Europe EGFR Inhibitors for Lung Cancer Sales by Type
7.3 Europe EGFR Inhibitors for Lung Cancer Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa EGFR Inhibitors for Lung Cancer by Country
8.1.1 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022)
8.1.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022)
8.2 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type
8.3 Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer
10.3 Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer
10.4 Industry Chain Structure of EGFR Inhibitors for Lung Cancer
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 EGFR Inhibitors for Lung Cancer Distributors
11.3 EGFR Inhibitors for Lung Cancer Customer
12 WORLD FORECAST REVIEW FOR EGFR INHIBITORS FOR LUNG CANCER BY GEOGRAPHIC REGION
12.1 Global EGFR Inhibitors for Lung Cancer Market Size Forecast by Region
12.1.1 Global EGFR Inhibitors for Lung Cancer Forecast by Region (2023-2028)
12.1.2 Global EGFR Inhibitors for Lung Cancer Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global EGFR Inhibitors for Lung Cancer Forecast by Type
12.7 Global EGFR Inhibitors for Lung Cancer Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer EGFR Inhibitors for Lung Cancer Product Offered
13.1.3 Pfizer EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 AstraZeneca
13.2.1 AstraZeneca Company Information
13.2.2 AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered
13.2.3 AstraZeneca EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 AstraZeneca Main Business Overview
13.2.5 AstraZeneca Latest Developments
13.3 Genentech (Roche Group)
13.3.1 Genentech (Roche Group) Company Information
13.3.2 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered
13.3.3 Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Genentech (Roche Group) Main Business Overview
13.3.5 Genentech (Roche Group) Latest Developments
13.4 Beta Pharma
13.4.1 Beta Pharma Company Information
13.4.2 Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered
13.4.3 Beta Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Beta Pharma Main Business Overview
13.4.5 Beta Pharma Latest Developments
13.5 Mylan
13.5.1 Mylan Company Information
13.5.2 Mylan EGFR Inhibitors for Lung Cancer Product Offered
13.5.3 Mylan EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Mylan Main Business Overview
13.5.5 Mylan Latest Developments
13.6 Boehringer Ingelheim
13.6.1 Boehringer Ingelheim Company Information
13.6.2 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered
13.6.3 Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Boehringer Ingelheim Main Business Overview
13.6.5 Boehringer Ingelheim Latest Developments
13.7 Teva Pharmaceuticals
13.7.1 Teva Pharmaceuticals Company Information
13.7.2 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.7.3 Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Teva Pharmaceuticals Main Business Overview
13.7.5 Teva Pharmaceuticals Latest Developments
13.8 Qilu Pharmaceutical
13.8.1 Qilu Pharmaceutical Company Information
13.8.2 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
13.8.3 Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Qilu Pharmaceutical Main Business Overview
13.8.5 Qilu Pharmaceutical Latest Developments
13.9 Betta Pharmaceuticals
13.9.1 Betta Pharmaceuticals Company Information
13.9.2 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.9.3 Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Betta Pharmaceuticals Main Business Overview
13.9.5 Betta Pharmaceuticals Latest Developments
13.10 Haosen Pharmaceutical
13.10.1 Haosen Pharmaceutical Company Information
13.10.2 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
13.10.3 Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Haosen Pharmaceutical Main Business Overview
13.10.5 Haosen Pharmaceutical Latest Developments
13.11 ARIAD Pharmaceuticals
13.11.1 ARIAD Pharmaceuticals Company Information
13.11.2 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.11.3 ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 ARIAD Pharmaceuticals Main Business Overview
13.11.5 ARIAD Pharmaceuticals Latest Developments
13.12 HUTCHMED
13.12.1 HUTCHMED Company Information
13.12.2 HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered
13.12.3 HUTCHMED EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 HUTCHMED Main Business Overview
13.12.5 HUTCHMED Latest Developments
13.13 Shanghai Ellis
13.13.1 Shanghai Ellis Company Information
13.13.2 Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered
13.13.3 Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Shanghai Ellis Main Business Overview
13.13.5 Shanghai Ellis Latest Developments
13.14 Genvio Pharma
13.14.1 Genvio Pharma Company Information
13.14.2 Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered
13.14.3 Genvio Pharma EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Genvio Pharma Main Business Overview
13.14.5 Genvio Pharma Latest Developments
13.15 Everest Pharmaceuticals
13.15.1 Everest Pharmaceuticals Company Information
13.15.2 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.15.3 Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Everest Pharmaceuticals Main Business Overview
13.15.5 Everest Pharmaceuticals Latest Developments
13.16 Incepta Pharmaceuticals
13.16.1 Incepta Pharmaceuticals Company Information
13.16.2 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
13.16.3 Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.16.4 Incepta Pharmaceuticals Main Business Overview
13.16.5 Incepta Pharmaceuticals Latest Developments
13.17 Jiangsu Hengrui Medicine
13.17.1 Jiangsu Hengrui Medicine Company Information
13.17.2 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered
13.17.3 Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales, Revenue, Price and Gross Margin (2020-2022)
13.17.4 Jiangsu Hengrui Medicine Main Business Overview
13.17.5 Jiangsu Hengrui Medicine Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. EGFR Inhibitors for Lung Cancer Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. EGFR Inhibitors for Lung Cancer Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Geftinib
Table 4. Major Players of Afatinib
Table 5. Major Players of Osimertinib
Table 6. Major Players of Other
Table 7. Global EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 8. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 9. Global EGFR Inhibitors for Lung Cancer Revenue by Type (2017-2022) & ($ million)
Table 10. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Type (2017-2022)
Table 11. Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022) & (US$/Unit)
Table 12. Global EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 13. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 14. Global EGFR Inhibitors for Lung Cancer Revenue by Application (2017-2022)
Table 15. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Application (2017-2022)
Table 16. Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022) & (US$/Unit)
Table 17. Global EGFR Inhibitors for Lung Cancer Sales by Company (2020-2022) & (K Units)
Table 18. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)
Table 19. Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022) ($ Millions)
Table 20. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)
Table 21. Global EGFR Inhibitors for Lung Cancer Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution and Sales Area
Table 23. Players EGFR Inhibitors for Lung Cancer Products Offered
Table 24. EGFR Inhibitors for Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global EGFR Inhibitors for Lung Cancer Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global EGFR Inhibitors for Lung Cancer Sales Market Share Geographic Region (2017-2022)
Table 29. Global EGFR Inhibitors for Lung Cancer Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global EGFR Inhibitors for Lung Cancer Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Country/Region (2017-2022)
Table 33. Global EGFR Inhibitors for Lung Cancer Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
Table 36. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
Table 37. Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
Table 39. Americas EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 40. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 41. Americas EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 42. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 43. APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022) & (K Units)
Table 44. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Region (2017-2022)
Table 45. APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC EGFR Inhibitors for Lung Cancer Revenue Market Share by Region (2017-2022)
Table 47. APAC EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 48. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 49. APAC EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 50. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 51. Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
Table 52. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
Table 53. Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
Table 55. Europe EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 56. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 57. Europe EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 58. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of EGFR Inhibitors for Lung Cancer
Table 68. Key Market Challenges & Risks of EGFR Inhibitors for Lung Cancer
Table 69. Key Industry Trends of EGFR Inhibitors for Lung Cancer
Table 70. EGFR Inhibitors for Lung Cancer Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. EGFR Inhibitors for Lung Cancer Distributors List
Table 73. EGFR Inhibitors for Lung Cancer Customer List
Table 74. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global EGFR Inhibitors for Lung Cancer Sales Market Forecast by Region
Table 76. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC EGFR Inhibitors for Lung Cancer Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC EGFR Inhibitors for Lung Cancer Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global EGFR Inhibitors for Lung Cancer Sales Market Share Forecast by Type (2023-2028)
Table 88. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global EGFR Inhibitors for Lung Cancer Sales Market Share Forecast by Application (2023-2028)
Table 92. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Application (2023-2028)
Table 94. Pfizer Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer EGFR Inhibitors for Lung Cancer Product Offered
Table 96. Pfizer EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. AstraZeneca Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 100. AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered
Table 101. AstraZeneca EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. AstraZeneca Main Business
Table 103. AstraZeneca Latest Developments
Table 104. Genentech (Roche Group) Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 105. Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered
Table 106. Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. Genentech (Roche Group) Main Business
Table 108. Genentech (Roche Group) Latest Developments
Table 109. Beta Pharma Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 110. Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered
Table 111. Beta Pharma EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. Beta Pharma Main Business
Table 113. Beta Pharma Latest Developments
Table 114. Mylan Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan EGFR Inhibitors for Lung Cancer Product Offered
Table 116. Mylan EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. Boehringer Ingelheim Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 120. Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered
Table 121. Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. Boehringer Ingelheim Main Business
Table 123. Boehringer Ingelheim Latest Developments
Table 124. Teva Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 125. Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 126. Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 127. Teva Pharmaceuticals Main Business
Table 128. Teva Pharmaceuticals Latest Developments
Table 129. Qilu Pharmaceutical Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 130. Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
Table 131. Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 132. Qilu Pharmaceutical Main Business
Table 133. Qilu Pharmaceutical Latest Developments
Table 134. Betta Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 135. Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 136. Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 137. Betta Pharmaceuticals Main Business
Table 138. Betta Pharmaceuticals Latest Developments
Table 139. Haosen Pharmaceutical Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 140. Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
Table 141. Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 142. Haosen Pharmaceutical Main Business
Table 143. Haosen Pharmaceutical Latest Developments
Table 144. ARIAD Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 145. ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 146. ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 147. ARIAD Pharmaceuticals Main Business
Table 148. ARIAD Pharmaceuticals Latest Developments
Table 149. HUTCHMED Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 150. HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered
Table 151. HUTCHMED EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 152. HUTCHMED Main Business
Table 153. HUTCHMED Latest Developments
Table 154. Shanghai Ellis Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 155. Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered
Table 156. Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 157. Shanghai Ellis Main Business
Table 158. Shanghai Ellis Latest Developments
Table 159. Genvio Pharma Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 160. Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered
Table 161. Genvio Pharma EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 162. Genvio Pharma Main Business
Table 163. Genvio Pharma Latest Developments
Table 164. Everest Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 165. Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 166. Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 167. Everest Pharmaceuticals Main Business
Table 168. Everest Pharmaceuticals Latest Developments
Table 169. Incepta Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 170. Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 171. Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 172. Incepta Pharmaceuticals Main Business
Table 173. Incepta Pharmaceuticals Latest Developments
Table 174. Jiangsu Hengrui Medicine Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 175. Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered
Table 176. Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 177. Jiangsu Hengrui Medicine Main Business
Table 178. Jiangsu Hengrui Medicine Latest Developments
Table 1. EGFR Inhibitors for Lung Cancer Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. EGFR Inhibitors for Lung Cancer Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Geftinib
Table 4. Major Players of Afatinib
Table 5. Major Players of Osimertinib
Table 6. Major Players of Other
Table 7. Global EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 8. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 9. Global EGFR Inhibitors for Lung Cancer Revenue by Type (2017-2022) & ($ million)
Table 10. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Type (2017-2022)
Table 11. Global EGFR Inhibitors for Lung Cancer Sale Price by Type (2017-2022) & (US$/Unit)
Table 12. Global EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 13. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 14. Global EGFR Inhibitors for Lung Cancer Revenue by Application (2017-2022)
Table 15. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Application (2017-2022)
Table 16. Global EGFR Inhibitors for Lung Cancer Sale Price by Application (2017-2022) & (US$/Unit)
Table 17. Global EGFR Inhibitors for Lung Cancer Sales by Company (2020-2022) & (K Units)
Table 18. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Company (2020-2022)
Table 19. Global EGFR Inhibitors for Lung Cancer Revenue by Company (2020-2022) ($ Millions)
Table 20. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company (2020-2022)
Table 21. Global EGFR Inhibitors for Lung Cancer Sale Price by Company (2020-2022) & (US$/Unit)
Table 22. Key Manufacturers EGFR Inhibitors for Lung Cancer Producing Area Distribution and Sales Area
Table 23. Players EGFR Inhibitors for Lung Cancer Products Offered
Table 24. EGFR Inhibitors for Lung Cancer Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global EGFR Inhibitors for Lung Cancer Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global EGFR Inhibitors for Lung Cancer Sales Market Share Geographic Region (2017-2022)
Table 29. Global EGFR Inhibitors for Lung Cancer Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global EGFR Inhibitors for Lung Cancer Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Country/Region (2017-2022)
Table 33. Global EGFR Inhibitors for Lung Cancer Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
Table 36. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
Table 37. Americas EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
Table 39. Americas EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 40. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 41. Americas EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 42. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 43. APAC EGFR Inhibitors for Lung Cancer Sales by Region (2017-2022) & (K Units)
Table 44. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Region (2017-2022)
Table 45. APAC EGFR Inhibitors for Lung Cancer Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC EGFR Inhibitors for Lung Cancer Revenue Market Share by Region (2017-2022)
Table 47. APAC EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 48. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 49. APAC EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 50. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 51. Europe EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
Table 52. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
Table 53. Europe EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
Table 55. Europe EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 56. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 57. Europe EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 58. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales by Application (2017-2022) & (K Units)
Table 66. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of EGFR Inhibitors for Lung Cancer
Table 68. Key Market Challenges & Risks of EGFR Inhibitors for Lung Cancer
Table 69. Key Industry Trends of EGFR Inhibitors for Lung Cancer
Table 70. EGFR Inhibitors for Lung Cancer Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. EGFR Inhibitors for Lung Cancer Distributors List
Table 73. EGFR Inhibitors for Lung Cancer Customer List
Table 74. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global EGFR Inhibitors for Lung Cancer Sales Market Forecast by Region
Table 76. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC EGFR Inhibitors for Lung Cancer Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC EGFR Inhibitors for Lung Cancer Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global EGFR Inhibitors for Lung Cancer Sales Market Share Forecast by Type (2023-2028)
Table 88. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global EGFR Inhibitors for Lung Cancer Sales Forecast by Application (2023-2028) & (K Units)
Table 91. Global EGFR Inhibitors for Lung Cancer Sales Market Share Forecast by Application (2023-2028)
Table 92. Global EGFR Inhibitors for Lung Cancer Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global EGFR Inhibitors for Lung Cancer Revenue Market Share Forecast by Application (2023-2028)
Table 94. Pfizer Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 95. Pfizer EGFR Inhibitors for Lung Cancer Product Offered
Table 96. Pfizer EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 97. Pfizer Main Business
Table 98. Pfizer Latest Developments
Table 99. AstraZeneca Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 100. AstraZeneca EGFR Inhibitors for Lung Cancer Product Offered
Table 101. AstraZeneca EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 102. AstraZeneca Main Business
Table 103. AstraZeneca Latest Developments
Table 104. Genentech (Roche Group) Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 105. Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Product Offered
Table 106. Genentech (Roche Group) EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 107. Genentech (Roche Group) Main Business
Table 108. Genentech (Roche Group) Latest Developments
Table 109. Beta Pharma Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 110. Beta Pharma EGFR Inhibitors for Lung Cancer Product Offered
Table 111. Beta Pharma EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 112. Beta Pharma Main Business
Table 113. Beta Pharma Latest Developments
Table 114. Mylan Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 115. Mylan EGFR Inhibitors for Lung Cancer Product Offered
Table 116. Mylan EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 117. Mylan Main Business
Table 118. Mylan Latest Developments
Table 119. Boehringer Ingelheim Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 120. Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Product Offered
Table 121. Boehringer Ingelheim EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 122. Boehringer Ingelheim Main Business
Table 123. Boehringer Ingelheim Latest Developments
Table 124. Teva Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 125. Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 126. Teva Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 127. Teva Pharmaceuticals Main Business
Table 128. Teva Pharmaceuticals Latest Developments
Table 129. Qilu Pharmaceutical Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 130. Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
Table 131. Qilu Pharmaceutical EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 132. Qilu Pharmaceutical Main Business
Table 133. Qilu Pharmaceutical Latest Developments
Table 134. Betta Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 135. Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 136. Betta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 137. Betta Pharmaceuticals Main Business
Table 138. Betta Pharmaceuticals Latest Developments
Table 139. Haosen Pharmaceutical Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 140. Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Product Offered
Table 141. Haosen Pharmaceutical EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 142. Haosen Pharmaceutical Main Business
Table 143. Haosen Pharmaceutical Latest Developments
Table 144. ARIAD Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 145. ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 146. ARIAD Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 147. ARIAD Pharmaceuticals Main Business
Table 148. ARIAD Pharmaceuticals Latest Developments
Table 149. HUTCHMED Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 150. HUTCHMED EGFR Inhibitors for Lung Cancer Product Offered
Table 151. HUTCHMED EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 152. HUTCHMED Main Business
Table 153. HUTCHMED Latest Developments
Table 154. Shanghai Ellis Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 155. Shanghai Ellis EGFR Inhibitors for Lung Cancer Product Offered
Table 156. Shanghai Ellis EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 157. Shanghai Ellis Main Business
Table 158. Shanghai Ellis Latest Developments
Table 159. Genvio Pharma Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 160. Genvio Pharma EGFR Inhibitors for Lung Cancer Product Offered
Table 161. Genvio Pharma EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 162. Genvio Pharma Main Business
Table 163. Genvio Pharma Latest Developments
Table 164. Everest Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 165. Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 166. Everest Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 167. Everest Pharmaceuticals Main Business
Table 168. Everest Pharmaceuticals Latest Developments
Table 169. Incepta Pharmaceuticals Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 170. Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Product Offered
Table 171. Incepta Pharmaceuticals EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 172. Incepta Pharmaceuticals Main Business
Table 173. Incepta Pharmaceuticals Latest Developments
Table 174. Jiangsu Hengrui Medicine Basic Information, EGFR Inhibitors for Lung Cancer Manufacturing Base, Sales Area and Its Competitors
Table 175. Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Product Offered
Table 176. Jiangsu Hengrui Medicine EGFR Inhibitors for Lung Cancer Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 177. Jiangsu Hengrui Medicine Main Business
Table 178. Jiangsu Hengrui Medicine Latest Developments
LIST OF FIGURES
Figure 1. Picture of EGFR Inhibitors for Lung Cancer
Figure 2. EGFR Inhibitors for Lung Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global EGFR Inhibitors for Lung Cancer Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global EGFR Inhibitors for Lung Cancer Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. EGFR Inhibitors for Lung Cancer Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Geftinib
Figure 10. Product Picture of Afatinib
Figure 11. Product Picture of Osimertinib
Figure 12. Product Picture of Other
Figure 13. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type in 2021
Figure 14. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Type (2017-2022)
Figure 15. EGFR Inhibitors for Lung Cancer Consumed in Medical Care
Figure 16. Global EGFR Inhibitors for Lung Cancer Market: Medical Care (2017-2022) & (K Units)
Figure 17. EGFR Inhibitors for Lung Cancer Consumed in Experiment
Figure 18. Global EGFR Inhibitors for Lung Cancer Market: Experiment (2017-2022) & (K Units)
Figure 19. EGFR Inhibitors for Lung Cancer Consumed in Others
Figure 20. Global EGFR Inhibitors for Lung Cancer Market: Others (2017-2022) & (K Units)
Figure 21. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Figure 22. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Application in 2021
Figure 23. EGFR Inhibitors for Lung Cancer Revenue Market by Company in 2021 ($ Million)
Figure 24. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company in 2021
Figure 25. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Geographic Region in 2021
Figure 27. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Region (2017-2022)
Figure 28. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Country/Region in 2021
Figure 29. Americas EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 30. Americas EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 31. APAC EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 32. APAC EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 33. Europe EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 34. Europe EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 37. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021
Figure 38. Americas EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021
Figure 39. United States EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Region in 2021
Figure 44. APAC EGFR Inhibitors for Lung Cancer Revenue Market Share by Regions in 2021
Figure 45. China EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 49. India EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021
Figure 52. Europe EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021
Figure 53. Germany EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 54. France EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021
Figure 59. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021
Figure 60. Egypt EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer in 2021
Figure 66. Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer
Figure 67. Industry Chain Structure of EGFR Inhibitors for Lung Cancer
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
Figure 1. Picture of EGFR Inhibitors for Lung Cancer
Figure 2. EGFR Inhibitors for Lung Cancer Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global EGFR Inhibitors for Lung Cancer Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global EGFR Inhibitors for Lung Cancer Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. EGFR Inhibitors for Lung Cancer Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Geftinib
Figure 10. Product Picture of Afatinib
Figure 11. Product Picture of Osimertinib
Figure 12. Product Picture of Other
Figure 13. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Type in 2021
Figure 14. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Type (2017-2022)
Figure 15. EGFR Inhibitors for Lung Cancer Consumed in Medical Care
Figure 16. Global EGFR Inhibitors for Lung Cancer Market: Medical Care (2017-2022) & (K Units)
Figure 17. EGFR Inhibitors for Lung Cancer Consumed in Experiment
Figure 18. Global EGFR Inhibitors for Lung Cancer Market: Experiment (2017-2022) & (K Units)
Figure 19. EGFR Inhibitors for Lung Cancer Consumed in Others
Figure 20. Global EGFR Inhibitors for Lung Cancer Market: Others (2017-2022) & (K Units)
Figure 21. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Application (2017-2022)
Figure 22. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Application in 2021
Figure 23. EGFR Inhibitors for Lung Cancer Revenue Market by Company in 2021 ($ Million)
Figure 24. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Company in 2021
Figure 25. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Geographic Region in 2021
Figure 27. Global EGFR Inhibitors for Lung Cancer Sales Market Share by Region (2017-2022)
Figure 28. Global EGFR Inhibitors for Lung Cancer Revenue Market Share by Country/Region in 2021
Figure 29. Americas EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 30. Americas EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 31. APAC EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 32. APAC EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 33. Europe EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 34. Europe EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue 2017-2022 ($ Millions)
Figure 37. Americas EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021
Figure 38. Americas EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021
Figure 39. United States EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC EGFR Inhibitors for Lung Cancer Sales Market Share by Region in 2021
Figure 44. APAC EGFR Inhibitors for Lung Cancer Revenue Market Share by Regions in 2021
Figure 45. China EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 49. India EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021
Figure 52. Europe EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021
Figure 53. Germany EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 54. France EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa EGFR Inhibitors for Lung Cancer Sales Market Share by Country in 2021
Figure 59. Middle East & Africa EGFR Inhibitors for Lung Cancer Revenue Market Share by Country in 2021
Figure 60. Egypt EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country EGFR Inhibitors for Lung Cancer Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of EGFR Inhibitors for Lung Cancer in 2021
Figure 66. Manufacturing Process Analysis of EGFR Inhibitors for Lung Cancer
Figure 67. Industry Chain Structure of EGFR Inhibitors for Lung Cancer
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
